z-logo
open-access-imgOpen Access
Analysis of Bruton’s Tyrosine Kinase Deficiency in Patients with Presumed X-Linked Agammaglobulinemia
Publication year - 2018
Publication title -
journal of clinical and experimental immunology
Language(s) - English
Resource type - Journals
ISSN - 2475-6296
DOI - 10.33140/jcei.03.01.04
Subject(s) - bruton's tyrosine kinase , x linked agammaglobulinemia , hypogammaglobulinemia , tyrosine kinase , immunology , gene , wiskott–aldrich syndrome protein , mutation testing , mutation , biology , antibody , cancer research , medicine , genetics , receptor , cell , actin cytoskeleton , cytoskeleton
X-linked agammaglobulinemia (XLA) is a fully penetrant X-linked recessive disorder characterized by the early onset of recurrent bacterial infections, profound hypogammaglobulinemia and a marked decrease in the number of B-lymphocytes [1]. The gene defective in XLA has been identified as a non-receptor proteine tyrosine kinase, BTK (Bruton´s tyrosine kinase) [2,3]. Over 600 mutations have been described in the BTK gene and they are spreaded throughout the gene [4]. Mutational analysis has revealed that there is considerable heterogeneity in the clinical spectrum of XLA, with atypical individuals having small numbers of mature B lymphocytes and some immnoglobulin production [5]. Analysis of Btk protein expression in primary cells of XLA patients has shown that the large majority of individuals do not express protein regardless of their mutation [6]. As it is yet known Btk is expressed not only in B cells but also in granulocytes and monocytes. In the present work we applied a flow cytometric test employing whole blood to detect Btk expression in monocytes to identify XLA patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here